IL-27/IL-35 EBI3 Subunit (Dimer), (Heterodimer), (Monomer) Antikörper
Kurzübersicht für IL-27/IL-35 EBI3 Subunit (Dimer), (Heterodimer), (Monomer) Antikörper (ABIN2665152)
Target
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- Dimer, Heterodimer, Monomer
-
Aufreinigung
- The antibody was purified by affinity chromatography.
-
Isotyp
- IgG2a
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 0.5 mg/mL
-
Buffer
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
-
- IL-27/IL-35 EBI3 Subunit
-
Andere Bezeichnung
- IL-27/IL-35 EBI3
-
Hintergrund
- EBI3 is an IL-12 p40-related protein that can heterodimerized with IL-12 p35 to form IL-35, or with an IL-12 p35-related protein, p28, to form IL-27. It is produced by antigen-presenting cells such as B cells, monocytes, and dendritic cells (DCs) following stimulation through TLR. It can regulate T cell differentiation and proliferation. Both IL-27 and IL-35 are anti-inflammatory cytokines that are able to inhibit Th17 generation, promote Th1 differentiation, increase cytolytic activity of CD8+ T cells, and impact B cell differentiation and immunoglobulin production. IL-35 is also involved in tumorigenesis and is a promising biomarker for assessing tumor progression and prognosis in clinical settings.
Target
-